Table 2 Primary outcome measures
| Â | Mean (SD) change from baseline to 26Â weeks | Mean (95% CI) changes from baseline (liraglutide vs placebo) | P value | |
|---|---|---|---|---|
Liraglutide (n = 23) | Placebo (n = 26) | |||
LV diastolic function | ||||
 E in mL/s (SD) | − 33 (59) | 23 (62) | − 56 (− 91 to − 21) | 0.002 |
 A in mL/s (SD) | 31 (77) | 23 (62) | 3 (− 35 to 41) | 0.88 |
 E/A (SD) | − 0.19 (0.31) | − 0.00 (0.17) | − 0.17 (− 0.27 to − 0.06) | 0.003 |
 Edec in mL/s2 × 10−3 (SD) | − 0.6 (0.6) | 0.3 (0.9) | − 0.9 (− 1.3 to − 0.4) | < 0.001 |
 Ea in cm/s (SD) | 0.4 (1.8) | − 0.2 (1.7) | 0.4 (− 0.6 to 1.4) | 0.40 |
 E/Ea (SD) | − 0.9 (2.6) | 0.6 (1.9) | − 1.8 (− 3.0 to − 0.6) | 0.005 |
LV systolic function | ||||
 Stroke volume in mL (SD) | − 4 (13) | 5 (12) | − 9 (−16 to −2) | 0.02 |
 Ejection fraction in (% (SD) | − 1 (5) | 1 (5) | − 3 (−6 to − 0.1) | 0.02 |
 Cardiac output in L/min (SD) | 0.0 (0.9) | 0.3 (1.1) | − 0.4 (− 0.9 to 0.2) | 0.21 |
 Cardiac index in L/min/m2 (SD) | − 0.0 (0.4) | 0.1 (0.5) | − 0.1 (− 0.4 to 0.1) | 0.27 |
 Peak ejection rate in mL/s (SD) | − 28 (89) | 24 (82) | − 46 (−95 to 3) | 0.07 |